Monitor the company's cash burn rate and upcoming pipeline catalysts (e.g., data readouts for bitopertin or DISC-0974) as the extended loan runway provides capital into 2028. The $30M draw signals active capital deployment, likely funding ongoing clinical trials. No pricing of Tranches 2/3 was disclosed, so the total potential debt is capped at an unknown amount.
Price Chart
Executive Summary
Disc Medicine amended its existing loan agreement with Hercules Capital, drawing $30M from Tranche 1-B and restructuring the remaining $50M Tranche 1-C into two $25M tranches. The amendment also extends draw periods for Tranches 2 and 3 to late 2027/2028 and defers the minimum cash covenant test to July 2028, providing extended financial flexibility for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Disc Medicine drew $30M under Tranche 1-B of the Hercules Capital loan agreement.
- The existing $50M Tranche 1-C was split into a $25M tranche available through March 31, 2027, and a $25M Tranche 1-D available through April 30, 2027.
- Draw periods for Tranche 2 and Tranche 3 advances were extended to December 15, 2027 and June 30, 2028, respectively.
- Minimum cash covenant initial testing date was deferred to July 1, 2028.
- No financial data (revenue, earnings, cash balance) was reported in the filing; figures are not available for analysis.
Financial Impact
Drew $30M of existing debt capacity; total available future draws up to $75M across three tranches ($25M Tranche 1-C, $25M Tranche 1-D, plus Tranches 2 and 3 of undisclosed size). No revenue or earnings data in filing.
Risk Factors
- Increased debt burden from the $30M draw and potential future draws; interest and covenants apply.
- No product revenue; company remains pre-commercial with dependency on clinical-stage pipeline success.
- Additional draws or amendments could dilute equity if debt converts or forces equity-linked financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-290542 |
| Document: 0001193125-26-290542-index-headers.html | 0001193125-26-290542 |
| Document: 0001193125-26-290542-index.html | 0001193125-26-290542 |
| Document: 0001193125-26-290542.txt | 0001193125-26-290542 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 9, 2026 22d ago | Press Release | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 3, 2026 28d ago | Insider Cluster | $79.23 $68.92 | ▲ +13.01% | ▲ +11.80% | $64.48 (+18.62%) |
Sep 2, 2026 29d ago | 144 | $79.37 $70.06 | ▼ −11.73% | ▼ −10.58% | $64.48 (−18.76%) |
Aug 27, 2026 5w ago | Insider Cluster | $82.55 $79.37 | ▼ −3.85% | ▼ −4.12% | $64.48 (−21.89%) |
Aug 18, 2026 6w ago | Insider Cluster | $80.32 $82.67 | ▲ +2.93% | ▲ +3.31% | $64.48 (−19.72%) |
Aug 14, 2026 6w ago | Insider Cluster | $80.05 $80.94 | ▲ +1.11% | ▲ +2.30% | $64.48 (−19.45%) |
Jul 30, 2026 9w ago | 8-K | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 30, 2026 9w ago | Press Release | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 14, 2026 11w ago | Insider Cluster | $76.02 $74.32 | ▼ −2.24% | ▼ −1.26% | $64.48 (−15.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access